Boryung Pharm (003850) — Free Cash Flow Generation Index

Latest as of September 2025: 0.90x

Boryung Pharm (003850) has a Free Cash Flow Generation Index of 0.90x as of September 2025. Free cash flow of ₩44.04 Billion represents 1% of operating cash flow (₩48.95 Billion). Explore Boryung Pharm capital spending ratio to see what proportion of operating cash flow is directed to capital expenditures.

FCF Generation Index

0.90x
Free Cash Flow / Operating CF

Free Cash Flow

₩44.04 Billion
KRW

Operating Cash Flow

₩48.95 Billion
KRW

Capital Expenditures

₩4.92 Billion
KRW

Boryung Pharm Free Cash Flow Generation Index (2009–2024)

Historical FCF Generation Index trend for Boryung Pharm across 12 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Boryung Pharm.

Annual Free Cash Flow Generation for Boryung Pharm (2009–2024)

Year-by-year Free Cash Flow Generation Index for Boryung Pharm. Check Boryung Pharm (003850) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Year FCG Index Free Cash Flow (KRW) Operating CF Capital Expenditures YoY Change
2024 0.75x ₩60.51 Billion ₩80.56 Billion ₩20.05 Billion ▲ +68.0%
2023 0.45x ₩18.88 Billion ₩42.22 Billion ₩23.35 Billion ▲ +113.1%
2022 -3.42x ₩-95.18 Billion ₩27.81 Billion ₩20.28 Billion ▼ -24325.8%
2021 0.01x ₩849.90 Million ₩60.17 Billion ₩16.13 Billion ▲ +105.3%
2020 -0.26x ₩-11.85 Billion ₩44.74 Billion ₩18.27 Billion ▲ +42.8%
2019 -0.46x ₩-21.76 Billion ₩47.00 Billion ₩67.02 Billion ▲ +1.1%
2018 -0.47x ₩-18.21 Billion ₩38.91 Billion ₩54.83 Billion ▼ -112.1%
2016 3.87x ₩36.19 Billion ₩9.36 Billion ₩26.83 Billion ▲ +150.5%
2012 1.54x ₩28.35 Billion ₩18.38 Billion ₩9.98 Billion ▼ -39.3%
2011 2.54x ₩23.35 Billion ₩9.19 Billion ₩14.16 Billion ▲ +13.8%
2010 2.23x ₩53.89 Billion ₩24.12 Billion ₩29.77 Billion ▼ -46.0%
2009 4.14x ₩14.87 Billion ₩3.59 Billion ₩11.28 Billion
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).